Trial Profile
Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- 01 Jun 2009 96-week results published in the Journal of Acquired Immune Deficiency Syndromes.
- 14 Aug 2008 New trial record.